These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37317722)

  • 21. Pharmacokinetic/Pharmacodynamic Analysis of Guselkumab for Treatment of Palmoplantar Pustulosis: Clinical Implications of Guselkumab Dose, Disease Severity, and Smoking in Japanese Patients.
    Iwaki Y; Shibata S; Hu C
    J Clin Pharmacol; 2022 Feb; 62(2):182-189. PubMed ID: 34382209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of oral methotrexate (MTX) monotherapy vs oral MTX plus narrowband ultraviolet light B phototherapy in palmoplantar psoriasis.
    Ara S; Mowla MR; Alam M; Khan I
    Dermatol Ther; 2020 Jul; 33(4):e13486. PubMed ID: 32356586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
    Bissonnette R; Haydey R; Rosoph LA; Lynde CW; Bukhalo M; Fowler JF; Delorme I; Gagné-Henley A; Gooderham M; Poulin Y; Barber K; Jenkin P; Landells I; Pariser DM
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):403-410. PubMed ID: 29055155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
    Gottlieb A; Sullivan J; van Doorn M; Kubanov A; You R; Parneix A; Hugot S; Milutinovic M
    J Am Acad Dermatol; 2017 Jan; 76(1):70-80. PubMed ID: 27707593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of effectiveness and safety of excimer lamp vs topical calcipotriol-clobetasol propionate combination in the treatment of palmoplantar psoriasis.
    Thakur A; Bishnoi A; Dogra S; Narang T
    Photodermatol Photoimmunol Photomed; 2018 Jul; 34(4):249-256. PubMed ID: 29419896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.
    Okubo Y; Morishima H; Zheng R; Terui T
    J Dermatol; 2021 Dec; 48(12):1838-1853. PubMed ID: 34453358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nail lesions in palmoplantar pustulosis and pustulotic arthro-osteitis impairs patients' quality of life: Suggesting new assessment tool of PPP nail lesions.
    Masuda-Kuroki K; Kawakami H; Abe N; Mori M; Tobita R; Fukushi R; Hiruma J; Takeda Y; Okubo Y
    J Dermatol Sci; 2022 Apr; 106(1):29-36. PubMed ID: 35307234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pack-year cigarette smoking affects the course of palmoplantar pustulosis.
    Putra-Szczepaniak M; Reich A; Jankowska-Konsur A; Czarnecka A; Bagłaj-Oleszczuk M; Hryncewicz-Gwóźdź A
    Adv Clin Exp Med; 2021 Feb; 30(2):189-195. PubMed ID: 33636060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study.
    Brunasso AM; Puntoni M; Aberer W; Delfino C; Fancelli L; Massone C
    Br J Dermatol; 2013 Jun; 168(6):1243-51. PubMed ID: 23301847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series.
    Xu Q; Wang X; Yang A; Wei G
    Infect Drug Resist; 2023; 16():5165-5172. PubMed ID: 37581169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.
    Mrowietz U; Bachelez H; Burden AD; Rissler M; Sieder C; Orsenigo R; Chaouche-Teyara K
    J Am Acad Dermatol; 2019 May; 80(5):1344-1352. PubMed ID: 30716404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
    Viswanathan HN; Mutebi A; Milmont CE; Gordon K; Wilson H; Zhang H; Klekotka PA; Revicki DA; Augustin M; Kricorian G; Nirula A; Strober B
    Value Health; 2017 Sep; 20(8):1174-1179. PubMed ID: 28964451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Palmoplantar Dermatoses on Quality of Life.
    Singhal R; Diwan NG; Nair PA
    Indian Dermatol Online J; 2018; 9(5):309-313. PubMed ID: 30258797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial.
    Terui T; Kobayashi S; Okubo Y; Murakami M; Zheng R; Morishima H; Goto R; Kimura T
    JAMA Dermatol; 2019 Oct; 155(10):1153-1161. PubMed ID: 31268476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis.
    He Z; Lu C; Basra MK; Ou A; Yan Y; Li L
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):109-15. PubMed ID: 22145712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. UVA1 vs. narrowband UVB phototherapy in the treatment of palmoplantar pustulosis: a pilot randomized controlled study.
    Su LN; Ren J; Cheng SM; Liu JL; Ding YF; Zhu NW
    Lasers Med Sci; 2017 Nov; 32(8):1819-1823. PubMed ID: 28699044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group.
    Badia X; Mascaró JM; Lozano R
    Br J Dermatol; 1999 Oct; 141(4):698-702. PubMed ID: 10583119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Etanercept in the treatment of palmoplantar pustulosis.
    Bissonnette R; Poulin Y; Bolduc C; Maari C; Provost N; Syrotuik J; Poulin-Costello CM; Nigen S
    J Drugs Dermatol; 2008 Oct; 7(10):940-6. PubMed ID: 19112757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rasch analysis of the dermatology life quality index (DLQI) in patients with mild to moderate-severe psoriasis.
    Madrigal-Cadavid J; Estrada-Acevedo J; Maria Jaramillo A; Jaramillo-Santacoloma L; Guarin S; Londoño A; Rojas-Gualdron D
    Indian J Dermatol Venereol Leprol; 2024 Jan; ():1-7. PubMed ID: 38314980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-Term Correlation of the Psoriasis Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index, before and after Treatment, in Patients with Skin and Nail Psoriasis.
    Prevezas C; Katoulis AC; Papadavid E; Panagakis P; Rigopoulos D
    Skin Appendage Disord; 2019 Nov; 5(6):344-349. PubMed ID: 31799260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.